Skip to main content
Displaying 150 of 2909 articles.
New findings on how past viral respiratory infections affect future, unrelated ones could lead to therapies for boosting general antiviral immunity—and potentially better pandemic preparedness.

New understanding of how the virus replicates could lead to new therapeutic targets for HBV.

Thomas Tuschl has devoted his career to making discoveries that bridge the gap between bench and business—and have resulted in entirely new classes of drugs.

Marraffini is honored for his pioneering research on the study of CRISPR-Cas systems.

New research suggests that the long sought-after environmental trigger for MS is a toxin produced by certain C. perfringens bacteria.

Birsoy is honored for groundbreaking research uncovering metabolic weaknesses of diseased cells, such as cancer, while shedding light on debilitating mitochondrial diseases and rare genetic disorders.

The labs of Ali Brivanlou and Charles M. Rice collaborated to refine a cell culture technology platform that grows genetically identical lung buds from human embryonic stem cells.

Just as the Rice lab’s work on HCV exposed that virus’s weaknesses, the hope is that this novel approach could do the same for HBV.

Researchers have long disagreed over whether ??T cells in the gut promote or discourage tumor growth, but new evidence suggests they have the capacity to do both.

The booster appears to galvanize memory B cells into producing potent and versatile antibodies that neutralize both the original virus and its many variants.
View
View